Weight regain after stopping GLP-1 medicines is a common concern in community discussions. People describe changes in hunger, routines and confidence, alongside very different weight trajectories. Those experiences matter, but clinical withdrawal studies are a better guide to the average pattern than a small set of success stories.

What studies show after stopping semaglutide or tirzepatide

In the STEP 1 extension, participants previously assigned semaglutide regained, on average, about two-thirds of their prior weight loss during the year after both treatment and the study’s lifestyle intervention ended. In SURMOUNT-4, switching from tirzepatide to placebo after initial treatment led to substantial regain, whereas continued treatment maintained and extended weight reduction. The trials used different designs, so their percentages should not be treated as interchangeable.

What community experiences add

  • People want to know how to respond when appetite changes.
  • Food routines, walking, strength-based activity and practical support are recurring areas of interest.
  • Cost, side effects and changing circumstances can affect decisions about continuing treatment.
  • A person’s progress includes wellbeing and function as well as the number on a scale.

Planning support for weight maintenance

A maintenance conversation should cover the reason for stopping, future review and what support is available if weight or other health measures change. NICE recommends support to help maintain weight loss when weight-management medicines are stopped. The appropriate plan depends on the person and the reason the medicine was prescribed.

Regain should not be treated as evidence of poor commitment. The trial findings are consistent with obesity being a long-term condition, and an individual anecdote cannot show that a particular routine prevents regain for everyone. Likewise, study averages do not mean every person will follow the same course.

More science explainers and Svelta Labs information are available at https://sveltalabs.com.

This article provides context for a discussion with the clinical team. It does not advise stopping, restarting, spacing injections or selecting a maintenance dose independently.

Sources

Wilding and colleagues: STEP 1 withdrawal extension, 2022: https://pubmed.ncbi.nlm.nih.gov/35441470/.

Aronne and colleagues: SURMOUNT-4 randomised withdrawal trial, JAMA: https://jamanetwork.com/journals/jama/fullarticle/2812936.

NICE NG246: Medicines and surgery: https://www.nice.org.uk/guidance/NG246/chapter/medicines-and-surgery.